Shots:

• The P-III RATIONALE 309 study involves assessing tislelizumab + gemcitabine + cisplatin vs PBO combined with gemcitabine + cisplatin as a 1L treatment in 263 patients in a ratio (1:1) with recurrent or metastatic NPC
• The study met its 1EPs of PFS at the interim analysis while the safety profile is consistent with its known risks- with no new safety signals identified with the addition of CT
• Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 mAb- designed to minimize binding to FcγR on macrophages

  Ref: Businesswire | Image: Businesswire